secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001564590-22-019285
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera Q1 2022 revenue $317M, net earnings $0.59/sh, up from $0.43/sh YoY
----------------------------------------------------------------------------

- Total revenue $316.6M (up 56% YoY from $202.7M); net earnings $168.6M ($0.59 basic EPS vs $0.43).
- Royalties from bamlanivimab/bebtelovimab contributed $307M of total revenue.
- Cumulative program starts reached 84 (up 56% YoY); discovery partners grew to 36 from 29.
- Cash, cash equivalents and marketable securities stood at $786.1M.
- R&D expenses rose to $26.4M from $12.4M YoY, driven by platform investment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000156459022019285/0001564590-22-019285-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000156459022019285/abcl-8k_20220510.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-019285

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer